Does Rallies show 13F holders for GMED?

Yes. Rallies tracks hedge fund and 13F ownership data for GMED, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GMED research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GMED. It does not provide personalized investment advice.

GMED (GLOBUS MEDICAL INC) Stock Analysis - Hedge Fund Holdings

GLOBUS MEDICAL INC (GMED) is a publicly traded Healthcare sector company. As of May 20, 2026, GMED trades at $84.53 with a market cap of $10.71B and a P/E ratio of 110.28. GMED moved +5.14% today. Year to date, GMED is -7.12%; over the trailing twelve months it is +36.41%. Its 52-week range spans $51.79 to $101.40. Analyst consensus is strong buy with an average price target of $110.90. Rallies surfaces GMED's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GMED stock?

Hedge funds tracked by Rallies that own GMED include Sculptor Capital, Bridgewater Associates, Maverick Capital, Pinebridge Investments, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for GLOBUS MEDICAL INC.

GMED Key Metrics

Key financial metrics for GMED
Metric	Value
Price	$84.53
Market Cap	$10.71B
P/E Ratio	110.28
EPS	$0.76
Dividend Yield	0.00%
52-Week High	$101.40
52-Week Low	$51.79
Volume	2.15M
Avg Volume	0
Revenue (TTM)	$2.52B
Net Income	$102.98M
Gross Margin	58.90%

Top Hedge Funds Holding GMED

Sculptor Capital holds 3.06M shares of GMED, changed +1.93% as of Mar 31, 2026.
Bridgewater Associates holds 330.46K shares of GMED, changed +16.26% as of Mar 31, 2026.
Maverick Capital holds 15.66K shares of GMED, changed +0.00% as of Mar 31, 2026.
Pinebridge Investments holds 5.72K shares of GMED, changed -29.16% as of Sep 30, 2025.
Centerbook Partners holds 4.38K shares of GMED, changed -88.11% as of Dec 31, 2025.

Latest GMED News

Globus Medical Q1 Sales Soar 27% to $759.9M, EPS Up 66.6% — May 7, 2026
Globus Medical jumps ahead of May 7 Q1 earnings catalyst and growth expectations — Apr 30, 2026
Globus Medical slips as FY2026 EPS estimates get trimmed ahead of May earnings — Apr 29, 2026
Globus Medical slides 3% as traders de-risk ahead of May 7 earnings — Apr 28, 2026
Globus Medical slips as traders de-risk ahead of May 7 Q1 earnings report — Apr 21, 2026

Recent GMED Insider Trades

Huller Kelly sold 20.00K (~$1.89M) on Feb 25, 2026.
Huller Kelly sold 10.00K (~$876.70K) on Feb 12, 2026.
Kline Kyle sold 3.59K (~$363.35K) on Jan 8, 2026.

GMED Analyst Consensus

12 analysts cover GMED: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $110.90.

Common questions about GMED

Who owns GMED stock?: Hedge funds tracked by Rallies that own GMED include Sculptor Capital, Bridgewater Associates, Maverick Capital, Pinebridge Investments, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for GLOBUS MEDICAL INC.
Does Rallies show 13F holders for GMED?: Yes. Rallies tracks hedge fund and 13F ownership data for GMED, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GMED research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GMED. It does not provide personalized investment advice.